NEW YORK (GenomeWeb) – Editas Medicine announced it has signed a three-year collaboration agreement with Cystic Fibrosis Foundation Therapeutics.

Under the terms of the agreement, CFFT will pay Editas up to $5 million to support discovery and development of CRISPR/Cas9-based therapies for cystic fibrosis. CFFT will also provide its network of experts to Editas. On its end, Editas has agreed to explore common mutations driving the disease as well as those not currently addressed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.